STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more
STAT
OCTOBER 23, 2024
Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. … Novo Nordisk has asked the U.S. appeals court ruling in its favor , Reuters writes.
257 
Let's personalize your content